

September 2023

Dear Distributor

Product Approval Information Document

You are receiving this Product Approval Information Document as you are involved in the distribution of an insurance product ('product') co-manufactured by Accelerant Insurance Europe SA/NV.

Please read this document carefully as it includes important information about the co-manufacturers, product and associated product approval process and fair value assessment.

Co-Manufacturers

Accelerant Insurance Europe SA/NV ('Accelerant') is an insurance company authorised under code 3193 and regulated by the by the National Bank of Belgium and the Financial Services and Markets Authority in Belgium. In the UK, Accelerant is deemed authorised by the Prudential Regulation Authority ('PRA') and subject to regulation by the Financial Conduct Authority ('FCA') and limited regulation by the PRA. Full details of Accelerant's regulatory status can be found at: www.accelins.com/regulatory-status/.

Accelerant co-manufactures products with carefully selected Managing General Agents ('MGAs'), with products underwritten and distributed exclusively through these MGAs. The name and contact details of the MGA involved in co-manufacturing the product detailed in this document are provided in the Product Information section on page 3.

Product Approval Process

In accordance with Accelerant's Product Oversight and Governance Policy, the product detailed in this document - please refer to the Product Information section on page 3 for details - has been reviewed and approved by the firm's Product Oversight Group. The product is subject to ongoing monitoring and formal periodic review by both Accelerant and the MGA as co-manufacturers. Where a significant adaptation to the product is proposed, it is reviewed and, where appropriate, approved prior to the adapted product being marketed or distributed to customers.

Fair Value Assessment

In accordance with the regulatory requirements outlined in PROD 4.2 of the FCA Handbook, the co-manufacturers have analysed a range of value measures and subsequently deemed the product outlined on page 3 to represent fair value to the customer.

To ensure the customer receives fair value from this product, care must be taken to ensure that no duplicate cover exists, for example, where another product has been purchased by a customer alongside a primary product (i.e. an add-on). Where additional services or products - including premium finance - are provided by you alongside this product and/or you receive remuneration in the form of commission and/or fees, this information will have formed part of the fair value assessment. In accordance with regulatory requirements, all commissions, fees and other charges passed onto the customer must be proportionate to the service provided and represent fair value.

Should you wish to:

- request further information on the product outlined in this document;
- request further information on the product approval process and/or fair value assessment;
- provide new information, or an amendment to information already provided, in relation to any additional service(s) and/or product(s) provided and/or any additional remuneration received (e.g. commission, fee or other charge); or
- highlight any concerns about whether the product provides fair value to the customer

please contact the MGA involved in co-manufacturing the product whose contact details can be found in the Product Information section on page 3.

Yours faithfully



Frank O'Neil
Chief Underwriting Officer

Product Information

Name of Product:	Corporate Medical Malpractice
Name of MGA:	ES Risks Europe EPE
MGA Contact Details:	suzanne.dunleavy@esrisks.eu
Date of Product Approval:	17/10/2023
Date of Fair Value Assessment:	17/10/2023
Target Market Description:	<p>Target market is SME clinics and professionals trading within the Republic of Ireland's private healthcare sector.</p> <p>Clients working within medical specialisms specified within approved underwriting guide.</p>
Unsuitable Market Description:	<p>Non ROI domiciled risks. Individual practitioners or clinics that require cover for surgeons and/or general practice on a primary basis. Specialisms stated as a decline within approved rating guide.</p>
Product Cover & Structure:	<p>Mandatory Covers MEDICAL MALPRACTICE DISCIPLINARY INQUIRY COSTS CORONERS INQUESTS LOSS OF DOCUMENTS COURT ATTENDENCE COSTS LIBEL AND SLANDER PUBLIC RELATIONS COST DEFENCE BREACH OF CONFIDENTIALITY BREACH OF INTELLECTUAL PROPERTY SUBCONTRACTORS</p> <p>Optional Covers ABUSE RUN OFF COVER</p>
Additional Information:	This document is to be read in conjunction with the policy wording and IPID or summary document.
Approved Distribution:	This product has been approved for retail and wholesale brokers.

Fair Value Over Time:

Time factors will apply if run off cover is either purchased at expiry or agreed within the premium at inception.

When run off cover is purchased at expiring, this will be quoted on a sliding scale as the probability of a claim decreases:

Period	% expiring premium
1st Year Run off	100%
2nd Year Run off	80%
3rd Year Run off	65%
4th Year Run off	50%
5th Year Run off	30%
6th Year Run off	25%
7th Year Run off	25%

Pricing Differentials:

There is no insurance premium differential applied directly based upon:

- a client's vulnerability or protected characteristics
- the choice of the client to use or not use a premium finance facility
- the client opting/not opting into an auto-renewal arrangement
- the number of policy periods the client has been covered by the product (tenure)